Published in Hypertension on June 01, 1991
20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol (2010) 1.55
Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2008) 1.54
Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. Free Radic Biol Med (2009) 1.06
Androgen-sensitive hypertension associates with upregulated vascular CYP4A12-20-HETE synthase. J Am Soc Nephrol (2013) 0.94
Nrf2 and cardiovascular defense. Oxid Med Cell Longev (2013) 0.91
11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension. Prostaglandins Other Lipid Mediat (2011) 0.78
Role of HO/CO in the Control of Peripheral Circulation in Humans. Int J Hypertens (2012) 0.76
Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II. Circ Res (1970) 2.23
Modulation by prostaglandins of adrenergic transmission in the isolated perfused rabbit and rat kidney. Circ Res (1975) 2.17
Selective passage of prostaglandins across the lung. Nature (1969) 1.92
Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med (1991) 1.91
Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res (1972) 1.68
Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science (1989) 1.67
Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest (2001) 1.54
Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase. Nature (1985) 1.49
Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. Hepatology (1996) 1.46
Genetic hypertension in rats is accompanied by a defect in renal prostaglandin catabolism. Nature (1976) 1.41
Updating prognosis of cirrhosis by Cox's regression model using Child-Pugh score and aminopyrine breath test as time-dependent covariates. Ital J Gastroenterol Hepatol (1998) 1.39
Prostaglandins and the kidney. Circ Res (1973) 1.38
Contribution of prostaglandins to the renal circulation in conscious, anesthetized, and laparotomized dogs. Circ Res (1977) 1.38
Dependency of renal blood flow on prostaglandin synthesis in the dog. Circ Res (1973) 1.37
Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol (2007) 1.34
Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol (1992) 1.33
Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science (1991) 1.32
Prostaglandin-like substances appearing in canine renal venous blood during renal ischemia. Their patial characterization by pharmacologic and chromatographic procedures. Circ Res (1970) 1.32
Prostaglandins and renal function. Fed Proc (1974) 1.31
Chloride anion concentration as a determinant of renal vascular responsiveness to vasoconstrictor agents. Br J Pharmacol (1993) 1.28
Prostaglandins and the regulation of uterine blood flow in pregnancy. Nature (1974) 1.26
Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol (1996) 1.25
The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2000) 1.24
Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol (1998) 1.23
Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol (2000) 1.21
Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis (2002) 1.18
Prostaglandin synthesis by bovine mesenteric arteries and veins. Circ Res (1975) 1.17
Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol (1987) 1.16
Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites. J Pharmacol Exp Ther (1992) 1.14
Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors. Br J Pharmacol (2004) 1.14
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2000) 1.13
12(R)-hydroxyicosatetraenoic acid: a cytochrome-P450-dependent arachidonate metabolite that inhibits Na+,K+-ATPase in the cornea. Proc Natl Acad Sci U S A (1987) 1.11
Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology (1992) 1.10
Cytochrome P450-derived renal HETEs: storage and release. Kidney Int (1997) 1.09
Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest (1999) 1.08
Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology (1994) 1.07
Differential effect of noradrenaline and renal nerve stimulation on vascular resistance in the dog kidney and the release of a prostaglandin E-like substance. Clin Sci (1972) 1.07
CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol Regul Integr Comp Physiol (2001) 1.07
Interrelations of the renal kallikrein-kinin system and renal prostaglandins in the conscious rat. Influence of mineralocorticoids. Circ Res (1978) 1.07
Modulation by 20-HETE of phenylephrine-induced mesenteric artery contraction in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension (2001) 1.06
Hyperpolarizing factors. Biochem Pharmacol (1997) 1.06
Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney Int (1990) 1.06
Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol (1996) 1.05
Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension (1995) 1.04
The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. Hepatology (1996) 1.04
Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol (1995) 1.03
Modulation and mediation of the action of the renal kallikrein-kinin system by prostaglandins. Fed Proc (1976) 1.03
Possible contributions of endogenous prostaglandins to the control of blood pressure. Circ Res (1975) 1.03
Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol (2000) 1.01
Proceedings: Possible contribution of prostaglandins to genetic hypertension in rats: identification of biochemical lesion. Br J Pharmacol (1975) 1.01
Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem (1993) 1.01
The actions of bradykinin and eledoisin in the canine isolated kidney: relationships to prostaglandins. Clin Sci Mol Med (1975) 1.00
Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest (1997) 1.00
Hypotensive and renovascular actions of 6-keto-prostaglandin E1, a metabolite of prostacyclin. Eur J Pharmacol (1979) 1.00
Metabolism of prostacyclin in blood vessels. J Biol Chem (1978) 1.00
Role of K+ channels in the vasodilator response to bradykinin in the rat heart. Br J Pharmacol (1994) 0.99
Interobserver and interequipment variability of echo-Doppler examination of the portal vein: effect of a cooperative training program. Hepatology (1995) 0.99
Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification. J Biol Chem (1980) 0.99
20-hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries. Eur J Pharmacol (1993) 0.99
Cytochrome P-450-dependent vasodilator responses to arachidonic acid in the isolated, perfused kidney of the rat. Circ Res (1991) 0.99
Relaxant responses of rabbit aorta: influence of cytochrome P450 inhibitors. J Pharmacol Exp Ther (1994) 0.99
Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens (1997) 0.98
Renal prostaglandins: possible regulators of the renal actions of pressor hormones. Nature (1970) 0.98
Primary and metastatic scirrrhous carcinoma of the rectum. AJR Am J Roentgenol (1979) 0.98
Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound Med Biol (2001) 0.98
Cytochrome P-450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb. Am J Physiol (1994) 0.97
Biological activity of the methyl esters of prostaglandin E2 and its (15S)-15-methyl analogue. Eur J Pharmacol (1974) 0.97
Dual effects of bradykinin on prostaglandin metabolism: relationship to the dissimilar vascular actions of kinins. Prostaglandins (1977) 0.97
Differential inhibition by prostaglandins of the renal actions of pressor stimuli. Prostaglandins (1973) 0.97
Novel renal arachidonate metabolites. Am J Med Sci (1988) 0.97
Regulation of arachidonic acid metabolism by cytochrome P-450 in rabbit kidney. Biochem J (1986) 0.96
A new class of lipid mediators: cytochrome P450 arachidonate metabolites. Thorax (2000) 0.96
Possible influence of intrarenal generation of kinins on prostaglandin release from the rabbit perfused kidney. Br J Pharmacol (1976) 0.96
Hepatic metabolism of prostacyclin (PGI2) in the rabbit: formation of a potent novel inhibitor of platelet aggregation. Biochem Biophys Res Commun (1980) 0.96
Arachidonic acid metabolism and urinary excretion of prostaglandins and thromboxane in rats with experimental diabetes mellitus. J Pharmacol Exp Ther (1985) 0.96
Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol Sci (2000) 0.95
Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res (1975) 0.95
Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol (1999) 0.95
Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome p450-derived arachidonate metabolites. Br J Pharmacol (1998) 0.94
A closed eye contact lens model of corneal inflammation. Part 2: Inhibition of cytochrome P450 arachidonic acid metabolism alleviates inflammatory sequelae. Invest Ophthalmol Vis Sci (1995) 0.94
Structural identification of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. J Biol Chem (1991) 0.94
Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am J Physiol (1999) 0.94
Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin. Br J Pharmacol (1982) 0.93
Isomers of 12-hydroxy-5,8,10,14-eicosatetraenoic acid reduce renin activity and increase water and electrolyte excretion. J Pharmacol Exp Ther (1990) 0.93
Role of endoperoxides in arachidonic acid-induced vasoconstriction in the isolated perfused kidney of the rat. Br J Pharmacol (1989) 0.93
Bartter's syndrome results from an imbalance of vasoactive hormones. Ann Intern Med (1977) 0.93
The relationship of the renal vascular activity of angiotensin II to the autonomic nervous system. J Clin Invest (1965) 0.92
A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J Lipid Res (1998) 0.92
Prostaglandin A1: antihypertensive and renal effects. Studies in patients with essential hypertension. Ann Intern Med (1971) 0.92
The role of NF-kappaB in the angiogenic response of coronary microvessel endothelial cells. Proc Natl Acad Sci U S A (1996) 0.92
19(S)-hydroxyeicosatetraenoic acid is a potent stimulator of renal Na+-K+-ATPase. Biochem Biophys Res Commun (1988) 0.92
Arachidonic acid metabolism in a cell suspension isolated from rabbit renal outer medulla. J Pharmacol Exp Ther (1984) 0.91
Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol (1998) 0.91
Prostaglandins, prostacyclin, and thromboxanes. Annu Rev Pharmacol Toxicol (1981) 0.91